Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now
NURIX THERAPEUTICS INC

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full U.S. share.T&Cs apply

Claim now
Kickstart your portfolio with a U.S. stock on us

About NRIX

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.

Find out what a historical investment in NURIX THERAPEUTICS INC would be worth today using our NRIX stock calculator.

Market Capitalisation

$1.64B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

1M

High today

$16.16

Low today

$15.59

Open price

$15.78

52-week high

$22.50

52-week low

$8.20

Ready to start your investing journey with Stake?

Open an account
Buying NRIX shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in NURIX THERAPEUTICS INC in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in NRIX

The ticker symbol for NURIX THERAPEUTICS INC is NRIX.

One share of NRIX is valued at $15.84 as of 17 May 2026.

As of 17 May 2026 NURIX THERAPEUTICS INC has a market cap of $1.64B.

The NURIX THERAPEUTICS INC 52-week high stock price is $22.50.

The NURIX THERAPEUTICS INC 52-week low stock price is $8.20.

Yes, the Stake investing platform allows you to buy NRIX shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake app

Invest in NRIX on Stake

  • Buy NRIX from US$3 brokerage
  • Invest in 9,500+ U.S. stocks and ETFs
  • Own a slice of NRIX from only US$10 with fractional shares
Get started

Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.

NRIX related stocks

Footer


Made in Australia

Sydney, Australia

Subscribe to our newsletter

By subscribing, you agree to our Privacy Policy.



Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2026 Stake. All rights reserved.